Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FULC 
Fulcrum Therapeutics Inc (FULC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: FULC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.07
1 Year Target Price $11.07
| 2 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.51% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 382.43M USD | Price to earnings Ratio - | 1Y Target Price 11.07 |
Price to earnings Ratio - | 1Y Target Price 11.07 | ||
Volume (30-day avg) 7 | Beta 2.81 | 52 Weeks Range 2.31 - 8.50 | Updated Date 09/16/2025 |
52 Weeks Range 2.31 - 8.50 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.77% | Return on Equity (TTM) -30% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 172101116 | Price to Sales(TTM) 5.12 |
Enterprise Value 172101116 | Price to Sales(TTM) 5.12 | ||
Enterprise Value to Revenue 117.4 | Enterprise Value to EBITDA -3.09 | Shares Outstanding 54091600 | Shares Floating 23764057 |
Shares Outstanding 54091600 | Shares Floating 23764057 | ||
Percent Insiders 1.82 | Percent Institutions 101.54 |
Upturn AI SWOT
Fulcrum Therapeutics Inc
Company Overview
History and Background
Fulcrum Therapeutics Inc. was founded in 2016. It is a clinical-stage biopharmaceutical company focused on developing therapies for genetically defined diseases. The company leverages its product engine to identify drug targets that can modulate gene expression and address the root cause of disease.
Core Business Areas
- Drug Development: Fulcrum focuses on developing small molecule therapies that target gene expression to treat rare genetic diseases.
Leadership and Structure
Robert J. Gould is the President and Chief Executive Officer. The organizational structure is typical of a biopharmaceutical company, with departments focused on research, development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Ftx-6058: Ftx-6058 is an investigational oral small molecule designed to increase expression of the fetal hemoglobin gene in patients with sickle cell disease (SCD). It is in phase 1 testing. Competitors will include companies developing therapies for Sickle Cell Disease
- Losmapimod: Losmapimod is Fulcrum's lead product candidate, in Phase 3 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Market share is prospective, pending FDA approval. Competitors will include companies developing supportive therapies for FSHD. No exact revenue is currently derived from Losmapimod, as it is pre-revenue.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and strong competition. There is a growing focus on precision medicine and therapies for rare diseases.
Positioning
Fulcrum is positioned as a company focused on genetically defined diseases with a novel approach to drug development by modulating gene expression. Its competitive advantage lies in its product engine and focus on FSHD with Losmapimod.
Total Addressable Market (TAM)
The estimated TAM for FSHD is significant, given the prevalence of the disease. Losmapimod's peak sales potential could reach several hundred million dollars annually if approved. Fulcrum is positioned to capture a substantial portion of this market.
Upturn SWOT Analysis
Strengths
- Novel drug development approach
- Lead product candidate in Phase 3 for FSHD
- Strong intellectual property portfolio
- Experienced management team
- Focus on genetically defined diseases
Weaknesses
- Reliance on a limited number of pipeline candidates
- High cash burn rate typical of biotech companies
- Regulatory and clinical trial risks
- Limited commercialization experience
Opportunities
- Potential FDA approval and commercialization of losmapimod
- Expansion of pipeline through internal discovery and partnerships
- Increasing awareness and diagnosis of FSHD
- Advancements in gene expression modulation technologies
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other companies developing FSHD therapies
- Patent challenges
- Market access and pricing pressures
Competitors and Market Share
Key Competitors
- ARRY
- GILD
- BIIB
Competitive Landscape
Fulcrum faces competition from established pharmaceutical companies and other biotechnology companies developing therapies for rare genetic diseases. Its competitive advantage lies in its novel approach to drug development and focus on FSHD.
Growth Trajectory and Initiatives
Historical Growth: Fulcrum's growth has been primarily driven by the advancement of its pipeline candidates through clinical trials. See above.
Future Projections: Future growth depends on the successful development and commercialization of losmapimod and other pipeline programs. See above.
Recent Initiatives: Recent initiatives include the advancement of losmapimod into Phase 3 clinical trials and continued research on other pipeline candidates.
Summary
Fulcrum Therapeutics is a clinical-stage company focused on developing therapies for genetically defined diseases, particularly FSHD. The successful trial for Losmapimod, in Phase 3 trials, can be a company driver. Fulcrum has a limited pipeline, is burning through cash, and needs regulatory approval to make revenue, which are areas to watch. The company's novel drug development approach gives it a competitive advantage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share estimates are approximations and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fulcrum Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2019-07-18 | CEO, President & Director Mr. Alexander C. Sapir | ||
Sector Healthcare | Industry Biotechnology | Full time employees 45 | Website https://www.fulcrumtx.com |
Full time employees 45 | Website https://www.fulcrumtx.com | ||
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.